MedTrace Logo

Plaqenil Role in Prevention of Age Related Macular Degeneration

NCT01541449 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2012-03-01

No results posted yet for this study

Summary

The investigators think that there is a connection between the use of plaquenil and the prevention of Age related macular degeneration (AMD). The investigators believe that the use of plaquenil makes bruch's membrane thicker, thereby preventing Chroidal Neovascularization (CNV) growth.

Conditions

  • Age Related Macular Degeneration

Sponsors & Collaborators

  • Ziv Hospital

    lead OTHER_GOV

Principal Investigators

  • Joseph pikkel, M.D · Ziv Medical Center

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Completion
2012-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01541449 on ClinicalTrials.gov